J. M. Cameron - Concepedia

Author

J. M. Cameron

Institute of Virology of the Slovak Academy of Sciences

Also Known As

Bearn, H Andersen, J Cameron, J M CAMERON, J M Cameron, J. M. CAMERON, J. M. Cameron, J.M. Cameron, Janet Cameron, Janet M. Cameron

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

Institute of Virology of the Slovak Academy of Sciences Jewish General Hospital GlaxoSmithKline (Germany)Parque Tecnológico de la Salud Supratek Pharma (Canada)

About

J. M. Cameron is an author at Institute of Virology of the Slovak Academy of Sciences specializing in medicine, virology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	20	3.9K
2	Natural Sciences	8	8	1.1K
3	Biochemistry	6	6	502
4	Engineering	2	2	36
5	Public Health	1	1	32

J. M. Cameron

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Rational design of potent sialidase-based inhibitors of influenza virus replication Mark von Itzstein, Wen‐Yang Wu, Gaik B. Kok, Nature Rational DesignMedicineAntiviral TherapySynthetic BiologyVirology	1993	1.8K
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase Charles A. Boucher, N. Cammack, P Schipper, Antimicrobial Agents and Chemotherapy	1993	319
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro Jonathon Alexis Coates, N. Cammack, H J Jenkinson, Antimicrobial Agents and Chemotherapy Bioorganic ChemistryImmunologyMolecular BiologyPharmacotherapyAntiviral Drug	1992	288
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro Jonathon Alexis Coates, N. Cammack, H J Jenkinson, Antimicrobial Agents and Chemotherapy ImmunologyPharmacotherapyAntiviral DrugImmunotherapyMedicinal Chemistry	1992	240
Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression C I, Thomas McKee, Jane Ryan, Journal of Virology Mutant In1814Viral ReplicationLow MultiplicityMolecular VirologyImmediate-early Gene Expression	1989	230
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine Qing Gao, Zhenyong Gu, Michael A. Parniak, Antimicrobial Agents and Chemotherapy MedicineHuman RetrovirusPathogenesisImmunologyAntiviral Therapy	1993	230
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine Zhengxian Gu, Qing Gao, Hengsheng Fang, Antimicrobial Agents and Chemotherapy Viral ReplicationGeneticsImmunologyMolecular BiologySite 65	1994	213
Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma Graham Hart, David Orr, Charles R. Penn, Antimicrobial Agents and Chemotherapy ImmunologyMolecular BiologyAntiviral DrugDna Polymerase GammaHuman Retrovirus	1992	170
Ribonucleotide Reductase Encoded by Herpes Simplex Virus Is a Determinant of the Pathogenicity of the Virus in Mice and a Valid Antiviral Target J. M. Cameron, I. Ross McDougall, H. S. Marsden, Journal of General Virology Viral ReplicationMolecular VirologyPathogenesisImmunologyHerpes Simplex Virus	1988	148
Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine N. Cammack, Philippa Rouse, Clara L.P. Marr, Biochemical Pharmacology BiosynthesisBiochemistryCellular MetabolismRedox BiologyEnantioselective Synthesis	1992	115

Page 1